medicines


Articles

Will a new US-led IP empire in India put access to medicines at risk?

25-Feb-2015 Financial Express Prof Brook K Baker, Professor of Law and Northeastern University, cautions that the Modi government’s accelerating flirtation with the US and its investors is dangerous to hundreds of millions of people worldwide whose lives depend on Indian generics

  • 10-Apr-2013 Act Up Paris
    L’accord de libre-échange entre l’UE et l’Inde met des millions de vies en danger

    Des militants de différents pays européens et des euro-députés se réunissent devant le Parlement européen pour réclamer l’abandon de dispositions mettant en danger l’accès aux médicaments.

  • 9-Apr-2013
    Join the rally to oppose EU-India FTA!

    Around 2000 people including people living with HIV (PLHIV), patient groups and public health activists will take to the streets and rally from Barakhamba road to Jantar Mantar at 11.00 am on 10 April 2013 to voice concerns and protest against harmful provisions being pushed by the EU-India FTA negotiations

  • 2-Apr-2013 First Post
    Manmohan Singh must learn from the Novartis judgement

    Will Manmohan Singh understand the clear purpose behind the national sentiment around the Supreme Court judgment on Novartis’ cancer drug Glivec? If he does, he should take a relook at the India-EU Free Trade Agreement that is cooking in his back-room.

  • 1-Apr-2013 LiveMint
    European Union sets tough conditions under FTA

    The gains accruing to the Indian generic drugs industry as a result of the Supreme Court judgement on the Novartis case may be lost if India accepts demands by the European Union (EU) under the proposed free trade agreement (FTA) between the two sides.

  • 27-Mar-2013
    Indian pharma sector fears India-European Union FTA could imperil local industry

    Drugmakers and healthcare activists are worried that the India-European Union Free Trade Agreement (FTA), which is in the works, may contain a provision that could imperil local industry and have urged the government to keep patent infringement issues out of FTAs.

  • 21-Mar-2013
    European Union-India FTA may hit generic medical industry

    The free trade agreement that European Union is pushing India to sign could put an end to India’s status as the pharmacy of the developing providing affordable medicines, especially HIV drugs to countries like Brazil, Thailand, South Africa, Zimbabwe and several others. The negotiations with EU are on at a feverish pace this week in Brussels even before the parliamentary standing committee looking into the free trade agreements (FTAs) has submitted its report.

  • 12-Mar-2013 New Medical
    Trans-Pacific Partnership Agreement: an interview with Judit Rius, Médecins Sans Frontières

    The TPP negotiators are making decisions that will affect at least 600 million people, and potentially hundreds of millions more, in complete secrecy, and this is unacceptable.

  • 6-Mar-2013
    EU-Thailand FTA negotiations: What fate for access to medicines?

    Health Action International Europe, Oxfam and Action against AIDS Germany have serious concerns over the repercussions the EU-Thailand FTA will have on access to medicines in Thailand and the region.

  • 5-Mar-2013 MSF
    As clock ticks toward Trans-Pacific trade pact deadline, US must end stall tactics on access to medicines

    As closed-door talks for the Trans-Pacific Partnership Agreement resume in Singapore this week, international medical humanitarian organization Médecins Sans Frontières calls on the US government to end its stall tactics and revise its proposals for what otherwise promises to be the most harmful trade deal ever for access to medicines in developing countries.

  • 1-Mar-2013 ABC
    TLC con UE hace peligrar los genéricos contra el sida en Tailandia, según ONG

    La fundación AIDS Access afirmó hoy que el tratado de libre comercio (TLC) entre Tailandia y la Unión Europea (UE) pondrá en peligro el acceso de los enfermos de sida a los medicamentos genéricos en el país asiático.

  • 22-Jan-2013 La Jornada
    Confirmado: el TPP extenderá las patentes

    La Cámara Nacional de la Industria Farmacéutica (Canifarma) evaluó en diciembre de 2012 los textos –que no son públicos– sobre propiedad intelectual del Acuerdo de Asociación Transpacífico (TPP por sus siglas en inglés) y su conclusión fue inequívoca: en ellos se busca extender los tiempos de duración de las patentes de medicamentos. La Asociación Mexicana de Laboratorios Farmacéuticos (Amelaf) ya había revelado las intenciones de las grandes farmacéuticas de Estados Unidos.

  • 30-Dec-2012 IPS
    Thai-EU FTA raises alarm for people with AIDS

    Days before leaders of the European Union arrived in Norway to collect this year’s Nobel Peace prize, Thai public health activists sent a letter to the northern powerhouse, warning that the EU’s 2012 accolades face a credibility test in this Southeast Asian country.

  • 16-Nov-2012 The Hook
    Canada prepares for drug patent concessions to clinch free-trade deal with EU

    As free trade talks with the European Union reach the endgame, Ottawa is signalling it is prepared to give the Europeans at least part of what they asked for on drug patents — a move that could cost Canadians up to $900 million a year.

  • 15-Nov-2012
    EU free trade deal will hike drug prices in N.S. — minister

    A concession on drug patents in a free trade deal with the European Union stands to cost Nova Scotians millions, Health and Wellness Minister David Wilson said Wednesday.

  • 14-Nov-2012 La Jornada, México
    TTP: pacientes, patentes, tratados y mercados

    Al decir de Hedwing Lindner –socia de Arochi, Marroquín&Lindner– el Acuerdo Estratégico Transpacífico de Asociación Económica (TPP, por su siglas en inglés) se negocia en lo "oscurito" en materia del capítulo de protección intelectual. Con ello se están protegiendo intereses del sector farmacéutico –al disminuir requisitos formales para otorgar patentes, extenderles vigencia (más de 20 años), aceptar las periféricas o secundarias y rechazar la bioequivalencia– en "detrimento" del desarrollo pleno de la industria nacional.

  • 26-Oct-2012 L’Express
    Accord UE-Israël sur les médicaments: un vote indigne du prix Nobel de la Paix

    Le 23 octobre 2012, le Parlement européen a approuvé l’ACAA, le protocole relatif à l’évaluation de la conformité et l’acceptation des produits industriels UE-Israël. L’ACAA n’est pas un simple accord technique commercial mais un acte politique très important.

  • 25-Oct-2012 Act Up-Paris
    ACTA, CETA, etc. Stop au déni de démocratie !

    Accord commercial Canada-UE (CETA), Accord de Libre Échange (ALE) UE-Inde, UE-Thaïlande, UE-Moldavie, etc. Tous ces accords contiennent potentiellement des clauses dangereuses pour les libertés des utilisateurs d’Internet, l’accès aux médicaments essentiels ou l’utilisation et la diffusion de logiciels libres.

  • 22-Oct-2012 AITEC
    EU trade policy cannot ignore the Geneva conventions: the European Parliament must reject the ACAA protocol with Israel

    Civil society statement calling fpr rejection of the Conformity Assessment and Acceptance of Industrial Products protocol attached to the European Union-Israel Association Agreement

  • 16-Oct-2012 La Presse Canadienne
    Brevets pharmaceutiques: un libre-échange coûteux?

    Les détracteurs des négociations de libre-échange entre le Canada et l’Union européenne crient victoire après la divulgation d’une étude confidentielle fédérale qui conclut que les concessions demandées au Canada dans un seul dossier pourraient coûter près de 2 milliards de plus par année aux Canadiens.

  • 27-Sep-2012 iPolitics
    US pharma companies could be real beneficiaries of Canada-EU trade deal

    Although the EU is asking Canada to change its patent regime, it is not possible to do so just for the EU. The actual beneficiaries would be all of the world’s brand-name companies. Of the world’s top 12 health care companies by revenue only three or four are resident in the EU.

  • 0 | 20 | 40 | 60 | 80 | 100 | 120 | 140 | 160 | ... | 480